SHANGHAI , Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced today announced with...
HONG KONG , Dec. 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the successful inclusion of all five of the Company's self-developed innovative drugs into the...
SAN FRANCISCO and SUZHOU, China , Dec. 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...
ABBOTT PARK, Ill. and INDIANAPOLIS , Dec. 6, 2025 /PRNewswire/ -- Amid the nation's worst blood shortage in a generation, the University of Wisconsin rallied Big Ten students, fans and alumni to...
SEOUL, South Korea , Dec. 6, 2025 /PRNewswire/ -- SK hynix Inc. (or "the company", www.skhynix.com ) announced today that it has been named the winner of the Best Financially Managed Semiconductor...
NEW YORK , Dec. 6, 2025 /PRNewswire/ --
NEW YORK , Dec. 6, 2025 /PRNewswire/ --
NEW YORK , Dec. 6, 2025 /PRNewswire/ --
VALBY, Denmark , Dec. 6, 2025 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced results from a long-term follow-up in patients who have received bexicaserin (LP352) for up to two years....
Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression and treatment-free following a single infusion as early as second line
Find more press releases from the following organizations